NeuroPace (NASDAQ:NPCE - Free Report) had its target price lifted by Cantor Fitzgerald from $19.00 to $20.00 in a research report sent to investors on Wednesday,Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the stock. Cantor Fitzgerald also issued estimates for NeuroPace's FY2025 earnings at ($0.54) EPS.
A number of other equities analysts also recently weighed in on NPCE. Wells Fargo & Company increased their price target on shares of NeuroPace from $13.00 to $17.00 and gave the stock an "overweight" rating in a research note on Thursday, January 30th. JPMorgan Chase & Co. increased their price target on shares of NeuroPace from $9.00 to $14.00 and gave the stock an "overweight" rating in a research note on Tuesday, December 17th. Finally, UBS Group assumed coverage on shares of NeuroPace in a research note on Tuesday, January 21st. They set a "buy" rating and a $17.00 price target on the stock. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $15.20.
Check Out Our Latest Stock Analysis on NPCE
NeuroPace Trading Down 1.6 %
NASDAQ NPCE traded down $0.18 during mid-day trading on Wednesday, reaching $11.00. 271,316 shares of the stock were exchanged, compared to its average volume of 120,525. NeuroPace has a 1-year low of $5.45 and a 1-year high of $15.77. The business's fifty day simple moving average is $12.73 and its 200 day simple moving average is $9.83. The stock has a market capitalization of $328.33 million, a PE ratio of -11.00 and a beta of 2.06. The company has a debt-to-equity ratio of 6.03, a quick ratio of 4.77 and a current ratio of 5.59.
NeuroPace (NASDAQ:NPCE - Get Free Report) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.07. The company had revenue of $21.47 million for the quarter, compared to the consensus estimate of $21.14 million. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. On average, research analysts anticipate that NeuroPace will post -1 earnings per share for the current fiscal year.
Insider Activity
In other NeuroPace news, insider Martha Morrell sold 78,334 shares of the firm's stock in a transaction on Friday, February 21st. The shares were sold at an average price of $13.72, for a total transaction of $1,074,742.48. Following the completion of the transaction, the insider now directly owns 81,993 shares of the company's stock, valued at $1,124,943.96. This trade represents a 48.86 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Ltd. Kck sold 5,270,845 shares of NeuroPace stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $9.40, for a total transaction of $49,545,943.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,352,479 shares of company stock valued at $50,670,217. Company insiders own 22.20% of the company's stock.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of the business. Wells Fargo & Company MN boosted its holdings in shares of NeuroPace by 54.2% in the 4th quarter. Wells Fargo & Company MN now owns 6,483 shares of the company's stock valued at $73,000 after buying an additional 2,279 shares during the period. BNP Paribas Financial Markets acquired a new position in shares of NeuroPace in the 4th quarter valued at about $29,000. Financial Advocates Investment Management boosted its holdings in shares of NeuroPace by 27.8% in the 4th quarter. Financial Advocates Investment Management now owns 23,000 shares of the company's stock valued at $257,000 after buying an additional 5,000 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of NeuroPace by 21.2% in the 4th quarter. Bank of New York Mellon Corp now owns 29,342 shares of the company's stock valued at $328,000 after buying an additional 5,133 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of NeuroPace by 1.8% in the 4th quarter. Geode Capital Management LLC now owns 322,973 shares of the company's stock valued at $3,615,000 after buying an additional 5,781 shares during the period. 78.83% of the stock is owned by institutional investors and hedge funds.
NeuroPace Company Profile
(
Get Free Report)
NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.
Further Reading
Before you consider NeuroPace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeuroPace wasn't on the list.
While NeuroPace currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
